NHS Counts Benefits Before Use

NHS England’s case for its £330 million Palantir data platform has run into a problem that is less technical than political: some of the hospital trusts it publicly says are already “realising benefits” say they are not using the system, are not live on it, or have not agreed any implementation timeline.

The Guardian reported on Nov. 2 that 29 trusts on NHS England’s benefits list gave that account in freedom of information responses. That matters because the federated data platform, or FDP, has been sold not just as software but as proof that a national AI-driven system can help hospitals work faster, from discharge planning to surgery scheduling. If the public record blurs the line between limited back-end connection and actual operational use, the argument for success changes with it.

Several trusts’ replies were stark. According to the Guardian, Epsom and St Helier said it was “not using FDP at the moment”; Kent and Medway said the FDP “is not currently live”; Mersey Care said it had “not yet gone live”; Nottingham University Hospitals said no implementation timeline had been agreed; and University Hospitals of North Midlands said it did not intend to roll the platform out in future.

NHS England did not retreat from its broader claim. It said nearly 140 trusts had reported benefits from the range of tools available on the platform, helping staff improve care and efficiency. The distinction appears to be doing heavy lifting. NHS England has previously said its tally includes trusts using tools for back-office data analysis and submission, not only direct patient-care applications. In at least one case cited by the Guardian, a trust recorded as “live” had infrastructure in place to support data submission rather than active operational use of FDP apps.

That is not a trivial definitional dispute. In health systems, “live” can mean a system is technically connected, partially deployed, or embedded in routine care. Those are very different stages. For hospital staff, they mean the difference between software that may eventually change work and software that actually has.

The controversy is sharpened by the way Palantir’s contract has already been defended. NHS England has said trusts using the FDP carried out 117,539 more operations over a year, but the Guardian reported that the service had already conceded it could not prove cause and effect. The Office for Statistics Regulation is now taking forward the question of how claims about trusts “realising benefits” were presented.

There is also an obvious trust issue here, and not only the digital kind. Patient-data platforms ask the public to accept large-scale coordination of sensitive information in exchange for promised practical gains. That exchange becomes harder to defend when ministers, managers and suppliers appear to be describing uptake more generously than the hospitals themselves do.

Critics of the contract, including MPs and campaigners, are calling for the government to use a 2027 break clause. Palantir rejects the criticism. Its UK and Europe chief executive, Louis Mosley, said ending the contract would put “politics above patients,” and the company says its software is helping hospitals deliver better care. Those are large claims in both directions. The evidence described by the Guardian is narrower but more concrete: dozens of trusts on a benefits list do not appear to recognise themselves in it.

For a system meant to join up fragmented records and make the NHS easier to run, the immediate picture is oddly fragmented. The software may be useful in some places. The reporting around it now needs to be.